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Abstract
Introduction Many of the DNA sequence variants identified in
the breast cancer susceptibility gene BRCA1  remain
unclassified in terms of their potential pathogenicity. Both
multifactorial likelihood analysis and functional approaches have
been proposed as a means to elucidate likely clinical
significance of such variants, but analysis of the comparative
value of these methods for classifying all sequence variants has
been limited.
Methods We have compared the results from multifactorial
likelihood analysis with those from several functional analyses
for the four BRCA1 sequence variants A1708E, G1738R,
R1699Q, and A1708V.
Results Our results show that multifactorial likelihood analysis,
which incorporates sequence conservation, co-inheritance,
segregation, and tumour immunohistochemical analysis, may
improve classification of variants. For A1708E, previously
shown to be functionally compromised, analysis of oestrogen
receptor, cytokeratin 5/6, and cytokeratin 14 tumour expression
data significantly strengthened the prediction of pathogenicity,
giving a posterior probability of pathogenicity of 99%. For
G1738R, shown to be functionally defective in this study,
immunohistochemistry analysis confirmed previous findings of
inconsistent 'BRCA1-like' phenotypes for the two tumours
studied, and the posterior probability for this variant was 96%.
The posterior probabilities of R1699Q and A1708V were 54%
and 69%, respectively, only moderately suggestive of increased
risk. Interestingly, results from functional analyses suggest that
both of these variants have only partial functional activity.
R1699Q was defective in foci formation in response to DNA
damage and displayed intermediate transcriptional
transactivation activity but showed no evidence for centrosome
amplification. In contrast, A1708V displayed an intermediate
transcriptional transactivation activity and a normal foci
formation response in response to DNA damage but induced
centrosome amplification.
Conclusion These data highlight the need for a range of
functional studies to be performed in order to identify variants
with partially compromised function. The results also raise the
possibility that A1708V and R1699Q may be associated with a
low or moderate risk of cancer. While data pooling strategies
may provide more information for multifactorial analysis to
improve the interpretation of the clinical significance of these
variants, it is likely that the development of current multifactorial
likelihood approaches and the consideration of alternative
statistical approaches will be needed to determine whether
these individually rare variants do confer a low or moderate risk
of breast cancer.
BRCT/DBD = BRCA1 C terminus domain/BRCA2 DNA-binding domain; CAT = chloramphenicol acetyltransferase; CK5/6 = cytokeratin 5/6; CK14 
= cytokeratin 14; DMEM = Dulbecco's modified Eagle's medium; ER = oestrogen receptor; FCS = foetal calf serum; IR = ionising radiation; kConFab 
= Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; LCL = lymphoblastoid cell line; LR = likelihood ratio; MSI 
= microsatellite instability; PCR = polymerase chain reaction; SNuPE = single nucleotide primer extension; TAD = transcriptional activation domain; 
UV = unclassified variant.Breast Cancer Research    Vol 9 No 6    Lovelock et al.
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Introduction
A significant proportion of inherited breast cancer is caused by
mutations in the BRCA1  and  BRCA2  tumour suppressor
genes which disrupt their role in cellular DNA repair, cell cycle
control, apoptosis, and tumour suppression (reviewed in [1]).
Although most mutations that are known to be pathogenic are
nonsense or stop mutations and thus are predicted to cause
mRNA decay or protein truncation, there are a significant
number of missense variants in the BRCA1  and  BRCA2
genes, the clinical consequences of which are unclear [2-5]. It
is important that the pathogenicity of these variants be under-
stood, for the benefit of breast cancer patients and their rela-
tives carrying such unclassified variants (UVs) and the
clinicians involved in their treatment.
A wide range of approaches for the classification of BRCA1
and BRCA2 sequence variants have been developed, which
include analysis of segregation data, sequence conservation,
and protein structure [3-13] and functional analysis based on
a range of in vitro assays [6-11,14]. Recently, multifactorial
likelihood prediction methods have been developed to use
data from a variety of sources, including histopathological fea-
tures of tumours, for the clinical evaluation of UVs [4]. Predic-
tions using this methodology currently rely heavily on data from
co-segregation in families and from co-inheritance of variants
with known pathogenic mutations in the same gene. Conse-
quently, very rare variants found in single or small families, and
also probable pathogenic variants that do not reach the appro-
priately stringent odds of causality of 1,000:1 suggested for
classification as pathogenic, remain formally unclassifiable
[4,5]. These findings provide a strong rationale for using func-
tional approaches to contribute additional data to support mul-
tifactorial predictions, with the caveat that such approaches
are most useful for assessment of variants located in known
functional domains for which in vitro functional assays have
been developed.
Building on our previous studies, we selected four UVs for
additional analyses, including tumour immunohistochemistry
using markers known to be associated with BRCA1 mutation
status [12], and in vitro assays to examine the effects on
BRCA1 function. The study included one variant we had pre-
viously classified as pathogenic by multifactorial likelihood
analysis (G1738R) and three variants that remained unclassi-
fied after multifactorial analysis (R1699Q, A1708V, and
A1708E) [3-5]. The A1708E variant acted as a positive con-
trol for functional assays since we and others [3,9,13] have
previously shown this variant to be functionally compromised.
All four variants map to the transcriptional activation domain
(TAD) and the putative interaction site for RNA polymerase II,
RNA helicase A, and multiple transcription factors [1]. We
present our comparison of multifactorial likelihood predictions
of pathogenicity and functional analysis of these BRCA1 vari-
ants.
Materials and methods
Tumour characterisation and revised multifactorial 
analysis
Patient recruitment and consent
As described previously [5], pedigrees with UVs in BRCA1
and BRCA2 were ascertained by the Kathleen Cuningham
Foundation Consortium for Research into Familial Breast Can-
cer (kConFab) according to eligibility criteria established by
the organisation [15,16]. With informed consent from partici-
pants, breast tumour sections from archival pathology speci-
mens were recalled for research studies. This research study
was approved by the human research ethics committees of the
Peter MacCallum Cancer Centre, the Queensland Institute of
Medical Research, and the University of Queensland.
Pathology review
Criteria for classifying tumours as 'BRCA1-like' or 'not
BRCA1-like' have been described previously [5].
Tumour immunohistochemistry
Oestrogen receptor (ER), cytokeratin 5/6 (CK5/6), and cytok-
eratin 14 (CK14) immunohistochemistry was carried out as
described previously [12].
Tumour microsatellite instability
Ten microsatellite markers (BAT25, BAT26, BAT40,
BAT34C4, D5S346, D17S250, ACTC, D18S55, D10S197,
and MYCL) were analysed for microsatellite instability (MSI)
status according to a previously established protocol [17].
Tumour tissue was compared with normal tissue. Tumourclas-
sification was as follows: MSI-high if three or more markers
demonstrated instability, MSI-low if one or two markers dem-
onstrated MSI, and MSI-stable if no marker exhibited MSI.
Prior probability of pathogenicity from amino acid 
conservation, and location of the mutation in specific known 
functional domains
Missense substitutions and in-frame deletions were classified
according to their location within one of two recognised func-
tional domains of the proteins, the C terminus region contain-
ing the BRCA1 BRCT repeats, defined loosely as amino acids
1,396 to 1,862, and the BRCA2 DNA-binding domain (amino
acids 2,500 to 3,098). Variants were also categorised accord-
ing to whether the wild-type residue involved in the substitu-
tion/deletion was evolutionarily conserved through to the
pufferfish  Tetraodon, using multiple sequence alignments
available on the Web site [18]. Heterogeneity analysis of
1,433 variants in the Myriad Genetic Laboratories, Inc. (Salt
Lake City, UT, USA) database was used to estimate the pro-
portion of Myriad deleterious variants in three classifications
[19]: (a) invariant position in BRCA1 C terminus domain/
BRCA2 DNA-binding domain (BRCT/DBD) domain, propor-
tion = 0.73; (b) variable position in BRCT/DBD domain, pro-
portion = 0.08; and (c) position outside of BRCT/DBD
domain, proportion = 0.02. The values were then used as priorAvailable online http://breast-cancer-research.com/content/9/6/R82
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probabilities of being deleterious for the classification of the
studied variants. All variants in this study fell within the BRCA1
BRCT domain.
Co-occurrence with pathogenic mutations
We queried the Myriad Genetic Laboratories, Inc. database of
approximately 100,000 full-sequence tests to determine the
number of times a UV was observed, and the number of differ-
ent deleterious mutations observed to co-occur with each var-
iant, as a measure of the number of times the UV is seen in
trans with a deleterious mutation. Phase of the variant and
mutation was established for a subset of individuals. Observa-
tions for variants were excluded if in cis with a mutation,
included if in trans with a mutation, and assumed to be in trans
with at least n - 1 observations for n observations with different
deleterious mutations of unknown phase.
Histopathology
Available invasive tumour sections were analysed for parame-
ters recognised to be associated with BRCA1 mutation status
[12,20,21]. Immunohistochemistry scoring was performed as
described previously [12]. Scoring was performed by a single
pathologist (SRL).
Pedigree causality analysis
Bayes factor analysis of families was performed as described
previously and incorporated no information additional to that
published previously [3,5].
Derivation of probabilities and multifactorial likelihood 
scoring
Probabilities were derived for each of the components
included in the study, under the assumption that each factor
was independent. For the co-occurrence component, we esti-
mated the likelihood that any given UV was causal, as
described previously [4]. The Bayes factor was included
directly as a likelihood ratio (LR) score for the pedigree analy-
sis component. Tumour expression of ER, CK5/6, and CK14
was used for calculating histopathological LR scores, based
on the previously reported prevalence of the combined immu-
notypes of these independent predictors of BRCA1 mutation
status in breast tumours [12]. The likelihoods for causality
were ER-positive (irrespective of cytokeratin score) = 0.14:1;
negative for all three markers = 0.87:1; ER-negative, CK14-
negative, CK5/6-positive = 5.6:1; ER-negative, CK14-posi-
tive, CK5/6-negative = 2.6:1; and ER-negative, CK14-posi-
tive, CK5/6-positive = 27.4:1. For the single ER-negative
grade 3 tumour with insufficient material available for cytoker-
atin analysis, the likelihood was calculated based on ER
expression and grade (LR 2.95:1), as described previously [5].
The individual LRs were multiplied to calculate an overall mul-
tifactorial LR, assuming statistical independence of the
sources of information. Bayes rule was then used to calculate
a posterior probability that the variant was deleterious from the
multifactorial LR and the prior probability as determined by
sequence alignment.
Functional analysis
BRCA1 cDNA plasmids
For the transcriptional activation assays, the pGal4B vector
and pGal4B vector containing a cDNA sequence encoding C-
terminal residues 1,528 to 1,863 (571 amino acids) of
BRCA1 containing TADs 1 and 2 [22] were kindly donated by
Jane Visvader (Walter and Eliza Hall Institute of Medical
Research, Melbourne, Australia). For generating control tem-
plates for single nucleotide primer extension (SNuPE) assays
and for the cytoplasmic localisation and centrosome amplifica-
tion assays, a pZeoSV plasmid containing the full-length
BRCA1 cDNA with or without UV [3] was used.
Generation of mutagenised BRCA1 cDNA plasmids
Mutations in BRCA1 cDNA plasmids were introduced using a
polymerase chain reaction (PCR)-mediated mutagenesis pro-
tocol as described previously [3] using Pfu  Turbo Taq
polymerase (Invitrogen Corporation, Carlsbad, CA, USA) and
the following primers incorporating the appropriate sequence
change (underlined, bold): BRCA1 1699Q forward 5'-gat gct
gag ttt gtg tgt gaa cag aca ctg aaa tat ttt cta gg-3', BRCA1
1699Q reverse 5'-cct aga aaa tat ttc agt gtc tgt tca cac aca
aac tca gca tc-3', BRCA1 1708V forward 5'-ctg aaa tat ttt cta
gga att gtg gga gga aaa tgg gta gtt ag-3', BRCA1 1708V
reverse 5'-cta act acc cat ttt cct ccc aca att cct aga aaa tat ttc
ag-3', BRCA1 1738R forward 5'-gag cat gat ttt gaa gtc aga
aga gat gtg gtc aat gga aga aac-3', and BRCA1 1738R
reverse 5'-gtt tct tcc att gac cac atc tct tct gac ttc aaa atc atg
ctc-3'. Mutagenic primers used to generate the BRCA1
1708E variant are described elsewhere [3]. Mutagenised
clones were confirmed by sequencing, and large-scale DNA
preps were made using commercial preparation kits (Qiagen
Inc., Valencia, CA, USA).
Cell culture
Lymphoblastoid cell lines (LCLs) were grown in RPMI with
10% foetal calf serum (FCS) and antibiotic/antimycotic
(Gibco-BRL, now part of Invitrogen Corporation). 293T cells
were cultured in Dulbecco's modified Eagle's medium
(DMEM) with 10% FCS and antibiotic/antimycotic. T47D cells
were cultured in RPMI media with 10% FCS, 10 μg/mL insu-
lin, and antibiotic/antimycotic. All cells were incubated at 37°C
in 5% CO2.
RNA extraction from cell lines
RNA was extracted from cell lines using Trizol Reagent (Invit-
rogen Corporation) according to the manufacturer's instruc-
tions and DNAse treated using the Ambion DNA-Free kit
(Ambion, Inc., Austin, TX, USA). cDNA was made from RNA
using the Invitrogen Superscript III Reverse Transcriptase kit
according to the manufacturer's instructions and used directly
in PCR.Breast Cancer Research    Vol 9 No 6    Lovelock et al.
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Single nucleotide primer extension assays
Templates for the SNuPE assay were generated by reverse
transcription-PCR of RNA extracted from LCLs and PCR of
the matching control plasmids (wild-type and mutagenised
BRCA1) using either of the primers described previously [3]
for the R1699Q, A1708V, and G1738R variants. PCR prod-
ucts from wild-type and mutagenised BRCA1 control tem-
plates and LCL cDNAs were then used in the SNuPE assay as
described previously [3] using the following primers:
SNuPE1699For 5'-gat gct gag ttt gtg tgt gaa c-3',
SNuPE1699Rev 5'-cct aga aaa tat ttc agt gtc-3',
SNuPE1708F 5'-ctg aaa tat ttt cta gga att g-3', SNuPE1708R
5'-gct aac tac cca ttt tcc tcc c-3', SNuPE 1738F 5'-gag cat
gat ttt gaa gtc aga-3', and SNuPE 1738R 5'-ttc ttc cat tga cca
cat ctc-3'. Radiolabelled products were resolved on a denatur-
ing polyacrylamide gel and visualised by autoradiography, as
described previously [3].
Tryptic digestion profiles
Plasmids carrying the mutagenised BRCA1 cDNA or wild-
type BRCA1 cDNA (1,571 base-pair product encompassing
exons 12 to 24) were used as templates to generate PCR
products with primers described previously [3] for the
R1699Q, A1708V, and G1738R variants. The PCR products
were transcribed and translated in vitro using the Promega
TNT Coupled Reticulocyte Lysate System and sulfur-35 L-
methionine (PerkinElmer, Melbourne, Australia) according to
the manufacturer's instructions. Protein products were
digested in increasing concentrations of trypsin and resolved
on a 14% acrylamide gel. Products were visualised using
autoradiography or the Typhoon™ Phosphorimaging system
(Amersham Biosciences, now part of GE Healthcare, Little
Chalfont, Buckinghamshire, UK).
Foci formation assays
MCF-7 human breast cancer cells were maintained in DMEM
supplemented with 10% FCS and grown at 37°C in a humid-
ified 5% CO2 atmosphere. Cells were seeded onto sterile
glass coverslips and transfected at 50% to 60% confluency
with 2 to 5 μg of plasmid DNA using Lipofectamine Reagent
(Invitrogen Corporation) according to the manufacturer's
instructions. At 6 hours after transfection, the transfection mix
was removed and replaced with DMEM containing 10% FCS.
At 44 hours after transfection, cells were either left untreated
or exposed to 15 Gy of radiation from a cesium-137 source
(Gammacell 1000 irradiator; Atomic Energy of Canada Lim-
ited, Mississauga, ON, Canada) and then allowed to recover
at 37°C for 4 hours. Cells were fixed in 3.7% formalin/PBS for
15 minutes, permeabilised in 0.2% Triton-PBS for 10 minutes,
and processed for immunostaining. Myc-tagged ectopic
BRCA1 was detected by immunofluorescence using the anti-
Myc rabbit polyclonal antibody A-14 (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA). Myc antibody was detected
with anti-rabbit Alexa Fluor 594 (Invitrogen Corporation). YFP-
BARD1 was co-transfected to ensure nuclear localisation of
BRCA1 isoforms. Cell nuclei were counterstained with the
chromosome dye Hoechst 33285 (Sigma-Aldrich, St. Louis,
MO, USA). The intranuclear foci localisation of each ectopic
protein was determined by scoring cells using an Olympus
BX40 epifluorescence microscope (Olympus, Tokyo, Japan),
and the proportion of cells displaying 0, 1 to 10, or greater
than 10 nuclear foci per cell was determined as previously
described [7]. Digital images were collected using a SPOT
camera. P values were determined using two-tailed t tests.
Centrosome amplification assays
293T cells were cultured on glass coverslips and transfected
with Myc-BRCA1 wild-type and mutant constructs using
Fugene 6 (Roche, Melbourne, Australia) according to the man-
ufacturer's instructions. For indirect immunofluorescence,
cells were fixed with cold methanol, permeabilised, and
stained with primary anti-centrin-2 (1:800) polyclonal (MC1,
kindly provided by Jeffrey Salisbury) and anti-Myc (9E10)
(1:200) monoclonal (Santa Cruz Biotechnology, Inc.) antibod-
ies 96 hours after transfection. Alexa 568 goat anti-mouse and
488 goat anti-rabbit secondary antibodies were subsequently
added, along with 1 μg/mL Hoechst (Molecular Probes Inc.,
now part of Invitrogen Corporation). Centriole numbers were
counted in a minimum of 100 Myc-expressing cells from each
of two independent experiments using a Zeiss LSM510 con-
focal microscope (Carl Zeiss, Jena, Germany).
BRCA1 transcriptional activation domain reporter assays
Human 293T and T47D cells were transiently transfected with
0.5  μg of the pG5CAT reporter plasmid and 1 μg of the
pGal4B plasmids described above in triplicate in six-well
plates using Fugene 6 according to the manufacturer's
instructions. Cell lysates were assayed for chloramphenicol
acetyltransferase (CAT) activity using the Roche CAT enzyme-
linked immunosorbent assay kit. CAT activity was normalised
to total cell extract protein assayed by the Bio-Rad Protein
Assay reagent (Bio-Rad Laboratories, Inc., Hercules, CA,
USA). P values were determined using two-tailed t tests.
Results
A description of the variants under study is shown in Table 1.
Based on our previously reported odds for causality using the
multifactorial likelihood analysis approach [5], together with
the established thresholds of greater than 1,000:1 for patho-
genicity and less than 1:100 for neutrality [4], G1738R was
classified at the start of this study as pathogenic, whereas
R1699Q, A1708V, and A1708E were considered unclassi-
fied. To further investigate the potential clinical significance of
these variants using the likelihood approach, we analysed the
tumours arising in carriers of these variants for ER and cytok-
eratin expression in order to extend the histopathology compo-
nent of the model and we updated and revised data for the co-
inheritance and sequence conservation components of the
model. We also performed a range of previously described
assays for BRCA1 function.A
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Table 1
Revised multifactorial likelihood analysis of BRCA1 unclassified variants
BRCA1 
variant
Previous 
multifactorial 
likelihood 
classification: odds 
for causalitya
Evolutionary 
conservation to 
Tetraodon and in 
BRCT domain
Sequence 
alignment 
prior 
probabilityb
Myriad 
frequency (in 
trans with 
deleterious 
mutation)
LR from 
co-occurrence 
with a deleterious 
mutation
Segregation 
analysis: 
Bayes factor
Tumour 
histology 
(number 
analysed)
Grade ER CK 5/6 CK14 LR
pathology
Multifactorial 
likelihood odds: 
co-occurrence, 
segregation, and 
pathology
Posterior 
probability of a 
variant being 
deleterious
BRCA1 
5215 G>A 
(R1699Q)
141:1 Invariant, to 
Tetraodon, 
inside BRCT
0.73 33 (0) 3.010 1.043 Not 
BRCA1-like 
(1)
1 Pos Neg Neg 0.14 0.440 0.543
BRCA1 
5242 C>T 
(A1708V)
41:1 Invariant, to 
Tetraodon, 
inside BRCT
0.73 6 (0) 1.220 0.227 BRCA1-like 
(1)
3 Neg NA NA 2.95 0.817 0.668
BRCA1 
5242 C>A 
(A1708E)
262:1 Invariant, to 
Tetraodon, 
inside BRCT
0.73 76 (0) 12.700 4.470 BRCA1-like 
(1)
3N e g P o s P o s
(focal)
27.38 1554.024 0.999
BRCA1 
5331 G>A 
(G1738R)
5871:1 Invariant, to 
Tetraodon, 
inside BRCT
0.73 8 (0) 1.300 20.250 BRCA1-like 
(1)
3N e g N e g P o s
(strong)
0.37 9.724 0.963
Not 
BRCA1-like 
(1)
0P o s N e g N e g
aChenevix-Trench and colleagues [5] and Lovelock and colleagues [3]; bEaston and colleagues [19]. CK, cytokeratin; ER, estrogen receptor; LR, likelihood ratio; NA, not applicable; Neg, negative; Pos, positive.Breast Cancer Research    Vol 9 No 6    Lovelock et al.
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Tumour characterisation and revised multifactorial 
analysis
We revised and extended our previous likelihood analysis as
described in Materials and methods. Specifically, sequence
conservation scores were interpreted as a prior probability
that incorporated amino acid position in known functional
domains of BRCA1 and BRCA2 [19], likelihoods for co-inher-
itance were from an updated dataset, segregation analysis
was as performed previously [3,5], and an amended his-
topathological likelihood was derived from either ER and
grade as in Chenevix-Trench and colleagues [5] or ER and
CK5/6 and CK14 as described in Materials and methods.
Incorporating this additional information gave posterior proba-
bilities of pathogenicity of 54.3% for R1699Q, 68.8% for
A1708V, 99.9% for A1708E, and 96.3% for G1738R (Table
1).
As detailed in Table 1, the data indicate that evolutionary anal-
ysis supported pathogenicity for all variants. Since no variants
co-occurred with deleterious mutations in the Myriad dataset,
the co-occurrence likelihoods provided relatively little informa-
tion, with the exception of A1708E, which is observed many
times in this dataset. Segregation analysis was most useful for
G1738R. Assessment of histological and immunohistochemi-
cal features of tumours from UV carriers showed that the sin-
gle tumour from an R1699Q carrier was not associated with
any tumour features commonly observed in BRCA1 high-risk
mutation carriers. The single tumours from carriers of A1708V
and A1708E were BRCA1-like, with the expected immunohis-
tochemical features. Tumours from two carriers of the
G1738R variant differed from each other in most respects,
with only one displaying features characteristic of BRCA1
tumours. Interestingly, even the cytokeratin expression profile
for the tumour with BRCA1-like morphological features was
only moderately suggestive of a causative mutation in the
BRCA1 gene (LR 2.6:1).
As an additional assessment of tumour characteristics, we
conducted MSI analysis of tumours since the BRCA1 BRCT
domain is known to bind to MLH1 and it has been suggested
previously that mutations in the BRCA1 BRCT domain may
cause mismatch repair deficiency [8]. Furthermore, limited evi-
dence from MSI analysis of a single tumour carrying a BRCA1
W1837R variant has been interpreted to suggest that mis-
sense mutations in the BRCT domain may present with a mic-
rosatellite-unstable tumour phenotype [8]. However, our
analysis of tumour DNA from the two G1738R carriers
showed that both tumours were microsatellite-stable.
Functional analysis of BRCA1 unclassified variants
To further characterise these variants, a range of functional
assays were performed (Figures 1 to 4 and summarised in
Table 2). As single nucleotide changes can affect mRNA and
protein stability, we first determined the levels of the products
Table 2
Summary of functional analyses on BRCA1 unclassified variants
BRCA1 variant Expression
(RNA and protein)
BRCT structure
(trypsin sensitivity)
Transcription
activation activity
Nuclear foci
formation
Centrosome
amplification
Conclusion
BRCA1 5215 
G>A (R1699Q)
Wild-type Destabilised Intermediate activity Defective Wild-type Intermediate on 1 and 
defective on 2 of 5 criteria
BRCA1 5242 
C>T (A1708V)
Wild-type Wild-type Intermediate activity Normal Positive Intermediate on 1 and 
defective on 1 of 5 criteria
BRCA1 5242 
C>A (A1708E)
Wild-type Destabilised No activity Defectivea Positive Defective on 4 of 5 criteria
BRCA1 5331 
G>A (G1738R)
Wild-type Destabilised No activity Defective Positive Defective on 4 of 5 criteria
aResults from assays performed in Lovelock and colleagues [3].
Figure 1
BRCA1 R1699Q causes destabilisation of the BRCT domain BRCA1 R1699Q causes destabilisation of the BRCT domain. In vitro-
transcribed and -translated BRCA1 cDNA fragments containing wild-
type or unclassified variant sequence, incorporating sulfur-35-labelled 
methionine, were treated with increasing concentrations of trypsin (μg/
mL) and resolved on SDS-PAGE.Available online http://breast-cancer-research.com/content/9/6/R82
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of gene expression from the UV allele, using SNuPE on LCLs
from carriers of each variant and in vitro transcription and
translation of cDNA constructs carrying these variants,
respectively. SNuPE analysis revealed no bias in expression
levels of either the wild-type or UV alleles in LCLs isolated from
BRCA1 UV carriers (data not shown). Similarly, in vitro tran-
scription and translation assays revealed no change in the lev-
els of protein product (Figure 1, zero dose). Thus, these
variants do not appear to effect either mRNA or protein stabil-
ity.
Amino acid substitutions in the BRCT domain of BRCA1 have
previously been shown to destabilise its structure and this is
associated with an increased susceptibility to trypsin-medi-
ated proteolysis [23,24]. Whereas previous studies have
shown this to be the case for G1738R [24] and A1708E [3],
the effect of R1699Q and A1708V on BRCT structure has not
been investigated. To address this, we carried out trypsin
digestion assays on radioactively labelled in vitro-translated
products derived from fragments of the BRCA1 cDNA. In the
proteolytic assays, the in vitro-translated products encoding
the A1708V variant showed tryptic digestion profiles similar to
those of the wild-type product at all trypsin concentrations
tested, whereas the protein products of R1699Q, G1738R,
and A1708E were degraded at and above 6 μg/mL of trypsin
(Figure 1 and data not shown). These results confirm previ-
ously published data on A1708E and G1738R and indicate
that the BRCT domain of R1699Q, but not A1708V, is desta-
bilised.
Several assays were carried out using an expression construct
encoding the BRCA1 TAD to ascertain any effects of
R1699Q, A1708V, and G1738R on the capacity of the region
to activate a co-transfected reporter construct in two inde-
pendent mammalian cell lines (Figure 2). BRCA1 A1708E was
also included as a UV known to be inactive in transcriptional
transactivation activity [3]. The G1738R and A1708E variants
abolished reporter activity to levels comparable to or below
those of the empty control vector. However, the A1708V and
R1699Q variants appeared to have an intermediate effect on
reporter activity. The magnitude of this effect was different
between the 293T cell line and the T47D cell line, with the lev-
els of reporter activity being approximately 55% of the wild-
type in the 293T cell line and approximately 20% of the wild-
type in the T47D cell line.
Cancer-associated mutations in BRCA1 can prevent nuclear
localisation of BRCA1 and its contribution to nuclear DNA
Figure 2
Transcriptional transactivation by C-terminal BRCA1 variants Transcriptional transactivation by C-terminal BRCA1 variants. (a) Graphical representation of results. Values are the mean and standard deviation of 
triplicate transfections. (b) Table showing means, standard deviations, and p values relative to vector and wild-type (wt) controls.Breast Cancer Research    Vol 9 No 6    Lovelock et al.
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repair foci formation in response to DNA damage (for example,
by ionising radiation [IR]) [6,7]. To determine whether the UVs
under study caused mislocalisation of BRCA1 and/or defects
in nuclear foci formation and therefore were likely to be patho-
genic, we transfected MCF-7 cells with the expression con-
structs and measured foci formation and cytoplasmic
localisation. As expected, wild-type BRCA1 and a known
benign variant (R496C) showed a strong increase in IR-induc-
ible nuclear foci (Figure 3). A similar, albeit variable, response
was seen in cells expressing BRCA1 A1708V. Although the
average percentage of cells containing greater than 10 foci is
lower than in cells expressing wild-type BRCA1, this differ-
Figure 3
Varied capacity of C-terminal BRCA1 variants to form foci in response to DNA damage Varied capacity of C-terminal BRCA1 variants to form foci in response to DNA damage. (a) Post-ionising radiation (IR) nuclear foci formation in cells 
co-transfected with the nuclear chaperone BARD1. (b) Summary of nuclear foci formation data in untreated cells and cells treated with IR. UV, 
unclassified variant; WT, wild-type.Available online http://breast-cancer-research.com/content/9/6/R82
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ence was not statistically significant (Figure 3b). In contrast,
cells expressing R1699Q and G1738R showed a significantly
diminished response, as we have reported previously for
A1708E using the same assay [3]. Together, these results
suggest that R1699Q, G1738R, and A1708E cause a defect
in the localisation and/or DNA damage response of BRCA1
whereas A1708V does not.
BRCA1 is involved in the regulation of centrosomes, and some
cancer-associated mutations are associated with centrosome
amplification [3,25]. We assayed centrosome amplification in
cells transfected with expression constructs carrying the UVs
to determine whether these UVs induced centrosome amplifi-
cation similarly to known deleterious mutations [3]. Centro-
some amplification in cells expressing BRCA1 R1699Q was
not significantly different from amplification in cells expressing
wild-type BRCA1 (Figure 4 and Table 2). In contrast, centro-
somes were more frequently amplified in cells expressing
BRCA1 A1708V, G1738R, and A1708E, the latter in agree-
ment with our previously published observations [3].
The results of the functional analyses of the variants investi-
gated in this study are summarised in Table 2. There was no
evidence to suggest that the variants may directly affect
mRNA or protein expression. A1708E and G1738R proteins
were defective in all other assays performed. In contrast,
R1699Q was defective for two assays and had intermediate
function for one assay (out of four assays), and A1708V had
intermediate function for the TAD assay, defective function in
a centrosome amplification assay, and normal function in a
nuclear foci formation assay. This suggests that R1699Q and
A1708V may confer partial BRCA1 activity.
Summary of results
A comparison of the conclusions from the original multifacto-
rial likelihood analysis, the revised multifactorial analysis incor-
porating revised evolutionary and co-occurrence components
and additional tumour features, and the functional data are
shown in Table 3. This comparison confirms previous reports
that BRCA1 A1708E is pathogenic. It provides functional evi-
dence of pathogenicity for G1738R which is supported by the
revised multifactorial analysis. The latter includes updated and
improved sequence conservation analysis and tumour immu-
nohistochemical analysis but has lost some power over previ-
ous analyses due to the necessary exclusion of loss of
heterozygosity data. This comparison also shows that the
R1699Q and A1708V variants, with only a moderate probabil-
ity of association with a high risk of cancer, are both at least
partially functionally compromised.
Discussion
Missense amino acid substitutions in BRCA1 and BRCA2 are
difficult to interpret. Multifactorial likelihood models incorporat-
ing a range of information therefore have been developed to
enable predictions to be made regarding their causality. The
Table 3
Summary of results
Variant Original odds
for causalitya
Original
conclusion
Posterior probability of 
pathogenicity from revised 
multifactorial likelihood 
analysis (Table 1)
Functional data
(Table 2)
Conclusion
BRCA1 R1699Q 141:1 UV 54.3% Intermediate on 1 and 
defective on 2 of 5 criteria
Possible low to moderate risk
BRCA1 A1708V 41:1 UV 68.8% Intermediate on 1 and 
defective on 1 of 5 criteria
Possible low to moderate risk
BRCA1 A1708E 262:1 UV 99.9% Defective on 4 of 5 criteria High risk
BRCA1 G1738R 5,871:1 Pathogenic 96.3% Defective on 4 of 5 criteria High risk
aChenevix-Trench and colleagues [5]. UV, unclassified variant.
Figure 4
Centrosome amplification Centrosome amplification. Graphical representation of percentage of 
cells transfected with BRCA1 wild-type and variants that display cen-
trosome amplification (greater than two centrosomes). Values are the 
mean and standard error of duplicate studies.Breast Cancer Research    Vol 9 No 6    Lovelock et al.
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underlying assumptions of these models are based on infor-
mation derived from classical high-risk mutation carriers and
predominantly truncating mutations, which currently classify
variants as either high-risk or of low clinical significance/neu-
tral. These models are therefore of clinical utility for predicting
the pathogenicity of the small subset of variants that are asso-
ciated with a high risk of disease. The ability of this approach
to distinguish between variants that are truly neutral and those
associated with a low risk of cancer is limited. Moreover, the
final predictions of pathogenicity are necessarily driven by the
availability of information on segregation and tumour pheno-
type (numbers of families and tumours available) and thus it is
difficult to assess whether apparent UVs may actually be asso-
ciated with a moderate risk of cancer. In addition, the model
assumes that missense mutations exhibit the same character-
istics (cancer risk and tumour phenotypes) as observed for
truncating mutations.
The results of this study show for the first time that incorporat-
ing data on the immunohistochemical characteristics of
tumours arising in carriers of these variants can sometimes
improve the prediction of pathogenicity. In the case of BRCA1
A1708E, which was previously classified as a UV using multi-
factorial likelihood analysis based on limited data, revised mul-
tifactorial analysis yielded a posterior probability of
pathogenicity of 99%. Tumour data contributed considerably
to this classification, with the presence of basal cytokeratin
markers and the absence of ER staining consistent with the
tumour phenotype of a defective BRCA1 gene. Together with
the functional data for this variant, the results provide evidence
that this missense variant exhibits the features of a classical
pathogenic BRCA1 mutation.
Our results also emphasise the fact that multifactorial predic-
tions must be viewed in light of the available data and the
underlying assumptions of the model, particularly the assump-
tion that BRCA1 missense mutation carriers are expected to
display classical 'BRCA1-like' features. Our previous analysis
of tumour immunohistochemical features of UV carriers sug-
gested disparate results for two tumours from G1738R carri-
ers, a result we confirm here with more detailed
immunohistochemical analysis of basal markers of the BRCA1
mutation phenotype. While it is possible that some tumours
occurring in BRCA1 carriers may be sporadic tumours not
driven by abnormalities in BRCA1, the ages at onset of the two
G1738R carriers (44 and 43 years) do not obviously point to
the possibility of a sporadic tumour on a BRCA1 mutation
background as an explanation for the observed data. It remains
to be tested whether missense mutation carriers will display
features similar to truncating mutations, but this will presuma-
bly require a large collaborative effort given the paucity of
known pathogenic missense mutations. However, we are cau-
tiously optimistic that at least a subset of BRCA1 missense
carriers will be identifiable from histopathological characteris-
tics. We have observed that two of the three tumours from car-
riers of functionally abrogated BRCA1 alleles display BRCA1-
like features. Moreover, access to unpublished core data from
the kConFab sample set has identified that breast tumours
from carriers of RING-finger domain mutations with available
pathology data (nine tumours) are all high-grade and those
with known receptor status (four tumours) are all ER-negative/
progesterone receptor-negative. It is important to note that our
previous pathogenic classification for G1738R was not driven
by immunohistopathology results but rather by the observation
of loss of the wild-type allele in both BRCA1 G1738R tumours
studied, data we excluded in this study due to the observation
that our loss of heterozygosity data on classified variants do
not support the underlying assumptions of the model. Never-
theless, the revised multifactorial data support the observation
that this variant exhibits the same functional deficiencies as the
A1708E variant, with a 96% posterior probability of patho-
genicity. This also supports other studies that report G1738R
as a founder Greek mutation [26], with reported odds of
11,470:1 for causality from analysis of seven Greek families
[27].
Importantly, our study has highlighted the fact that the multi-
factorial approach will require development to assess whether
a variant is associated with a low or moderate risk of cancer.
Revised multifactorial analysis incorporating tumour features
did not strongly support a high risk for either R1699Q or
A1708V, with posterior probabilities perhaps suggestive of a
moderately increased risk. Although this may appear to agree
with the fact that functional assays suggest that both variants
are at least partially functionally comprised, it should be noted
that the posterior probabilities were driven by the sequence
alignment component of the analysis. It is likely that the individ-
ual components of the multifactorial approach may have differ-
ent predictive power to assess variants that are associated
with a lower risk of cancer, and development of the current
multifactorial model and/or alternative statistical approaches
will need to be considered to test the hypothesis that variants
of intermediate function may be associated with an intermedi-
ate risk of cancer.
In this study, we did not include analysis of tumour loss of het-
erozygosity as a component of the multifactorial analysis, as
done previously [5], since interrogation of published and
unpublished data we have generated for a range of UVs has
revealed increased loss of the variant compared with that
expected for the underlying hypothesis used to calculate like-
lihood estimates, irrespective of their final classification. This
suggests that the underlying assumptions for this component
may not be appropriate for the classification of missense vari-
ants.
We also carried out a range of assays for the variants under
study to provide novel and supporting data toward a more
comprehensive description of the functional defects, if any,
associated with these variants. Results from functional analy-Available online http://breast-cancer-research.com/content/9/6/R82
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ses of variants are largely supported by sequence alignment
and protein modelling predictions. Sequence alignment and
BRCA1 R1699Q maps to the N-terminal BRCT motif of the
TAD suggest that it is deleterious, whereas modelling and in
vitro proteolytic assays indicate that the variant may affect the
structure or conformation of the BRCT domain [23]. Func-
tional analysis of this variant suggests that it may partially com-
promise BRCA1 function. TAD assays in 293T and T47D
mammalian cells indicated an intermediate phenotype, 56% of
wild-type in 293T cells and 23% of wild-type in T47D cells
(Figure 4). This intermediate activity is consistent with similar
analyses performed by Vallon-Christersson and colleagues
[9], who showed approximately 20% activity of R1699Q in
293T cells. The difference in the level of activity may reflect dif-
ferences in the cDNA construct and reporter system used. In
other assays, R1699Q was either defective (nuclear foci for-
mation) or indistinguishable from wild-type (centrosome ampli-
fication). Taken together, these findings suggest that this
variant causes a significant yet incomplete loss of BRCA1
function.
The A1708V variant is also located in the N-terminal BRCT
motif of BRCA1. Replacement of an alanine residue with a
valine at this position is predicted to affect the conformation of
BRCA1 by causing an incompatibility with a bend structure in
the helix [5] and it is possible that this predicted change may
have functional effects. However, to date, no functional data
have been presented for this variant. Here, we showed that
A1708V possesses reduced transcriptional transactivation
activity in two independent cell lines, similar to the R1699Q
variant, and that it induces centrosome amplification. In con-
trast, this variant caused no significant change in nuclear foci
formation.
The G1738R is located in the interval between the N- and C-
terminal BRCT motifs. This induces a conformational change
in BRCA1 which renders it susceptible to tryptic digestion
[23], and a recent report of transcriptional activity from assays
in yeast and mammalian cells indicates pathogenicity for this
variant [28]. This is supported by results from our mammalian
transcription transactivation assays, in which we observed a
reduced transactivation capacity of G1738R similar to that of
the deleterious variant A1708E. In addition, we have shown
that nuclear foci formation and centrosome amplification are
compromised to levels similar to that observed for the A1708E
missense variant, commonly considered to be pathogenic [3].
Collectively, current data from functional analysis of the
G1738R variant reported here and elsewhere [28] suggest
that it exhibits functional characteristics of a true pathogenic
mutation.
Our functional analysis of the A1708E TAD variant confirms
our previous findings [3] that this variant is deleterious. In addi-
tion, we have extended our previous multifactorial likelihood
analysis and now provide convincing evidence for pathogenic-
ity using this approach, with a posterior probability of patho-
genicity of 99%.
The overall results from multifactorial and functional analyses
highlight the known limitation of multifactorial analysis in that it
was not designed to distinguish between variants that are truly
neutral and those associated with a moderate or low risk of
cancer. The need to address or circumvent this limitation is
obvious from the increasing number of reports of low to mod-
erate risk genetic variants contributing to breast cancer [29-
33] and recent evidence that rare variants of known breast
cancer genes (including BRCA1 and BRCA2) act additively
or multiplicatively to significantly increase cancer risk at the
individual level [34].
Our multifactorial analysis indicates that both R1699Q and
A1708V are not high-risk  variants, but functional analyses
have shown that each displays either intermediate or defective
phenotype in some but not all assays (Table 2), raising the
possibility that these variants may be associated with a low to
moderate risk of cancer. Interestingly, whereas both variants
display intermediate activity with respect to transcriptional
transactivation, only R1699Q appears defective in nuclear foci
formation and only A1708V induced centrosome amplifica-
tion. Foci formation is known to be dependent on an intact
BRCT structure [7], and our results using trypsin sensitivity
analysis of BRCT structure are consistent with this, with
R1699Q displaying BRCT destabilisation and defective foci
formation whereas A1708V is normal on both counts. Our
results also suggest that transcriptional transactivation activity
is likely to involve a region of the C terminus other than that tar-
geted by trypsin digestion and suggest that the domains
involved on foci formation and the regulation of centrosomes
are likely to be independent. Given that these specific func-
tional assays to some extent examine discrete activities of the
BRCA1 protein, it would be preferable in the shorter term to
use a battery of tests to assess altered function. However,
given that the ultimate aim of an effective functional test is to
have the minimum number of robust test results, ultimately an
assay that measures general tumour suppressor activity is
required. Such an assay would be expected to reflect the con-
tribution of multiple overlapping and independent activities
and also to establish whether loss of a single activity may be
sufficient to disrupt its overall function as a tumour suppressor.
Unfortunately, although the most reliable functional assays
may improve estimates of the level or type of compromised
function, they are unlikely at this stage to provide a direct trans-
lation to measures of cancer risk. An alternative study design
such as large collaborative case-control studies [35], or
pooled family studies assessing risk associated with variant of
similar functional capacity, may be required to provide better
estimates of cancer risk associated with variants of intermedi-
ate functional phenotype.Breast Cancer Research    Vol 9 No 6    Lovelock et al.
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Conclusion
Our results suggest that the addition of tumour immunohisto-
chemical expression can add value to the classification of likely
causal BRCA1 variants using multifactorial likelihood analysis
and that functional assays are a useful adjunct to multifactorial
analysis. We also show that use of data from a range of assays
may be required to identify variants of moderately reduced
function, and we suggest that modified or alternative statistical
approaches will be required to assess whether such variants
are associated with a low to moderate risk of cancer.
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